Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Brownell, 2013, Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer, Clin Cancer Res, 19, 1347, 10.1158/1078-0432.CCR-12-0928 Farci, 2000, The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies, Science, 288, 339, 10.1126/science.288.5464.339 Nakano, 2012, An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region, Liver Int, 32, 339, 10.1111/j.1478-3231.2011.02684.x Alexopoulou, 2012, Current progress in the treatment of chronic hepatitis C, World J Gastroenterol, 18, 6060, 10.3748/wjg.v18.i42.6060 Abacioglu, 1995, The distribution of hepatitis C virus genotypes in Turkish patients, J Viral Hepat, 2, 297, 10.1111/j.1365-2893.1995.tb00045.x Ferenci, 2012, Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow, Best Pract Res Clin Gastroenterol, 26, 463, 10.1016/j.bpg.2012.09.002 Kuruuzum, 2013, Management of Chronic Hepatitis C Treatment, Türkiye Klinikleri J Inf Dis-Special Topics, 6, 59 Chayama, 2015, HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy, Viruses, 7, 5328, 10.3390/v7102876 Strader, 2004, American Association for the Study of Liver Diseases, Diagnosis, management, and treatment of hepatitis C, Hepatology, 39, 1147, 10.1002/hep.20119 Hadziyannis, 2004, PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med, 140, 346, 10.7326/0003-4819-140-5-200403020-00010 Kieffer, 2010, Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs), J Antimicrob Chemother, 65, 202, 10.1093/jac/dkp388 Sarrazin, 2010, Resistance to direct antiviral agents in patients with hepatitis C virus infection, Gastroenterology, 138, 447, 10.1053/j.gastro.2009.11.055 Jacobson, 2011, ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912 Zeuzem, 2011, REALIZE Study Team. Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086 Thompson, 2011, Resistance to anti HCV protease inhibitors, Curr Opin Virol, 1, 599, 10.1016/j.coviro.2011.10.001 Kuntzen, 2008, Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients, Hepatology, 48, 1769, 10.1002/hep.22549 López-Labrador, 2008, Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates, Antivir Ther, 13, 481, 10.1177/135965350801300413 Trimoulet, 2011, Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients, HIV Med, 12, 506, 10.1111/j.1468-1293.2011.00913.x Tuncer-Ertem, 2015, Cross Resistance to HCV NS3 Inhibitor Developing During Treatment With Peginterferon, Ribavirin and Telaprevir. Klimik J, 28, 92, 10.5152/kd.2015.18 Poordad, 2011, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494 Bacon, 2011, HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med, 364, 1207, 10.1056/NEJMoa1009482 Mohd Hanafiah, 2013, Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence, Hepatology, 57, 1333, 10.1002/hep.26141 Aygen, 2014, Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases, Klimik J, 2, 19 Tozun, 2015, Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study, Clin Microbiol Infect, 21, 1020, 10.1016/j.cmi.2015.06.028 2014, EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, J Hepatol, 60, 392, 10.1016/j.jhep.2013.11.003 Sayan M. Protease inhibitors drug resistance analysis in Turkey. KLIMIK Viral Hepatitis Study Group Workshop. Telaprevir experienced in Turkey. 21 Sept 2013, Istanbul, Turkey. www.klimik.org.tr. Wang, 2015, Direct acting Antiviral Agents Resistance associated Polymorphisms in Chinese Treatment naive Patients Infected with Genotype 1b Hepatitis C Virus, Chin Med J (Engl), 128, 2625, 10.4103/0366-6999.166038 Chen, 2016, Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data, Sci Rep, 6, 20310, 10.1038/srep20310 Andonov, 2013, Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba, Can J Gastroenterol, 27, 414, 10.1155/2013/273856 Hoffmann, 2013, Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study, Virol J, 10, 57, 10.1186/1743-422X-10-57 Palanisamy, 2013, Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a, Antiviral Res, 99, 12, 10.1016/j.antiviral.2013.04.018 Fried, 2013, Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study, Hepatology, 58, 1918, 10.1002/hep.26641 Izquierdo, 2014, Simeprevir for the treatment of hepatitis C virus infection, Pharmgenomics Pers Med, 7, 241 World Health Organization. New recommendations in the updated who guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Available from: URL: http://apps.who.int/iris/bitstream/10665/204452/1/WHO_HIV_2016.01_eng.pdf?ua=1 Manns, 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment naive patients with chronic hepatitis C virus genotype 1 infection (QUEST 2): A randomised, double blind, placebo controlled phase 3 trial, Lancet, 384, 414, 10.1016/S0140-6736(14)60538-9 Donaldson, 2015, Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir, Hepatology, 61, 56, 10.1002/hep.27375 Hézode, 2015, Daclatasvir plus peginterferon alfa and ribavirin for treatment naive chronic hepatitis C genotype 1 or 4 infection: A randomised study, Gut, 64, 948, 10.1136/gutjnl-2014-307498 Aygen, 2015, Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey, Balkan Med J, 32, 266, 10.5152/balkanmedj.2015.15366 Sargin-Altunok E, Aynioglu A, Akhan S, Sayan M. Kocaeli experienced in chronic hepatitis C. XVII. Turkish KLİMİK Congress. 25-29 March, 2015. Antalya-Turkey. P08-13, p:253. http://www.klimik.org.tr/klimik2015/?sayfa=ana_sayfa.